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AbstrAct
Objective Neutralising pro-inflammatory interleukin-6 
(IL-6) may effectively treat Crohn’s disease (CD). Effects 
of PF-04236921, an anti-IL-6 antibody, in adults with CD 
are reported.
Design Parallel-group, dose-ranging, double-blind trial 
with 4-week screening and 12-week treatment periods. 
After induction, patients entered 28-week follow-up 
or 48-week open-label extension (OLE) with 28-week 
follow-up. Adults with confirmed CD and inadequate 
response to anti-tumour necrosis factor (TNF) therapy 
were included. Induction study: 249 patients randomised 
1:1:1:1 to placebo, PF-04236921 10, 50 or 200 mg by 
subcutaneous injection on days 1 and 28. OLE study: PF-
04236921 50 mg every 8 weeks up to six doses followed 
by 28-week follow-up.
results 247 patients were randomised and received 
treatment in the induction study. The 200 mg dose was 
discontinued due to safety findings in another study 
(NCT01405196) and was not included in the primary 
efficacy analysis. Crohn’s Disease Activity Index (CDAI)-
70 response rates with PF-04236921 50 mg were 
significantly greater than placebo at weeks 8 (49.3% 
vs 30.6%, P<0.05) and 12 (47.4% vs 28.6%, P<0.05) 
and met the primary end point. Week 12 CDAI remission 
rates with PF-04236921 50 mg and placebo were 27.4% 
and 10.9%, respectively (16.5% difference; P<0.05). 
191 subjects received treatment in the OLE. Common 
treatment-emergent and serious adverse events in both 
studies included worsening CD, abdominal pain and 
nasopharyngitis.
conclusions PF-04236921 50 mg induced clinical 
response and remission in refractory patients with 
moderate-to-severe CD following failure of anti-TNF 
therapy. GI abscess and perforation were observed, 
a specific focus of attention during future clinical 
development.
trial registration number NCT01287897 and 
NCT01345318.
IntrODuctIOn
Crohn’s disease (CD) is a chronic inflamma-
tory condition of the GI tract with no known 
cure. Antibody-based therapies directed against 
tumour necrosis factor (TNF)1–3 or interleukin 12/
interleukin 23 p40 subunit antibody4 or integrins 
(α4β7/α4β1 integrin, α4β7 integrin)4 have demon-
strated efficacy in moderate-to-severe CD. Despite 
these options, up to 50% of patients experience 
primary non-response and more than 50% can 
lose response over time to anti-TNF maintenance 
therapy, so that dose adjustment, or switch to a 
different anti-TNF or non-anti-TNF therapy, is 
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significance of this study
What is already known on this subject?
 ► Crohn’s disease (CD) has no known cure.
 ► The cytokine interleukin-6 (IL-6) has multiple 
pro-inflammatory effects such as inhibition of 
apoptosis in mucosal T-cells and is a logical 
target for treating CD.
 ► PF-04236921 is a fully human immunoglobulin 
G2 monoclonal antibody that binds to human 
IL-6.
What are the new findings?
 ► CD Activity Index (CDAI)-70 response and 
remission rates with PF-04236921 50 mg 
were significantly greater than placebo in the 
induction study.
 ► Common treatment-emergent and serious 
adverse events in both studies included 
worsening CD, abdominal pain and 
nasopharyngitis. The benefit/risk profile for 
PF-04236921 is acceptable for the continued 
development of this treatment in this refractory 
CD population. Signals of GI perforation and 
abscess require careful consideration during 
future clinical development.
How might it impact on clinical practice in the 
foreseeable future?
 ► These studies are relevant in light of the limited 
therapeutic options available to difficult-to-
treat patients with CD who experience primary 
non-response, relapse or intolerance to anti-
tumour necrosis factor therapy.
 ► In addition, the studies support growing 
understanding of the potential of targeting IL-6 
for the treatment of inflammatory conditions.
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required.5 This leaves a significant unmet need in the treat-
ment of non-responsive patients, particularly after therapy with 
anti-TNF antibodies.
The cytokine interleukin-6 (IL-6) has multiple pro-inflamma-
tory effects such as inhibition of apoptosis in mucosal T-cells 
and is a logical target for treating CD.6 A small (n=36) 12-week, 
placebo-controlled pilot study of the IL-6 receptor inhibitor, 
tocilizumab, in moderate-to-severe CD suggested a clinical 
benefit.7
PF-04236921 is a fully human immunoglobulin G2 mono-
clonal antibody that binds to human IL-6 and has a half-life of 
36–51 days. In phase I trials in healthy volunteers and patients 
with rheumatoid arthritis (protocol B0151001, NCT00838565 
and NCT01166555), intravenous and subcutaneous (SC) 
PF-04236921 was well tolerated and caused sustained suppres-
sion of C-reactive protein (CRP), a marker for inflammation 
that is transcriptionally controlled by IL-6.8 PF-04236921 has 
also been investigated in a phase II trial in patients with systemic 
lupus erythematosus (SLE; NCT01405196).9 While the study 
did not meet the primary end point, improvement was noted 
in the primary as well as key secondary end points with 10 mg.
In this phase II trial, the efficacy, pharmacokinetics, safety, 
tolerability and immunogenicity of PF-04236921 were assessed 
in patients with moderate-to-severe CD, who were inadequate 
responders to anti-TNF therapy. It was followed by an open-
label extension (OLE) study with the primary objective of 
assessing the long-term safety, tolerability and immunogenicity 
of PF-04236921.
MetHODs
Patients
In this multicentre, phase II, randomised study, patients were aged 
18–75 years and had moderate-to-severe CD (Crohn’s Disease 
Activity Index (CDAI) score 220–450) with CRP ≥5.0 mg/L and 
ulceration demonstrated by colonoscopy within 8 weeks before 
screening. All patients had failed ≥1 anti-TNF therapy due to 
primary non-response, loss of response, intolerance or another 
reason. Permitted and prohibited treatments and study exclusion 
criteria are described in the online supplementary file.
Patients were enrolled in the OLE study if they had completed 
the blinded 12-week induction period. Patients were excluded 
from the OLE study if they had experienced a serious adverse 
event (SAE) related to treatment with PF-04236921 during the 
primary study or if there was a contraindication to ongoing 
treatment.
Protocols were approved by the relevant institutional review 
boards or ethics committees. Both studies complied with the 
ethical principles of the Declaration of Helsinki and the Inter-
national Conference on Harmonization Good Clinical Prac-
tice Guidelines. Safety was reviewed throughout the studies by 
an external data monitoring committee (DMC). All patients 
provided written, informed consent.
study design
This parallel-group, dose-ranging, double-blind phase II induc-
tion trial ( ClinicalTrials. gov identifier: NCT01287897) involved 
a 4-week screening period and a 12-week treatment period. 
Patients were planned to be randomised 1:1:1:1 to receive 
placebo or PF-04236921 10, 50 or 200 mg SC, on days 1 and 
28. Randomisation was performed using a computer-gener-
ated randomisation scheme, with stratification by background 
immunosuppressive therapy (azathioprine, six mercaptopurine, 
methotrexate or none) and reason for prior anti-TNF failure. 
Dose regimens were selected to provide a range of CRP suppres-
sion, based on pharmacokinetic pharmacodynamic modelling of 
phase I data.
After the induction period, patients entered either a 28-week 
follow-up period or the 48-week OLE study to receive 
PF-04236921 50 mg every 8 weeks followed by a 28-week 
follow-up period (NCT01345318). To enter the OLE, patients 
were required to complete the induction period but were not 
required to be considered responders. In the OLE, a one-time 
dose escalation to 100 mg was allowed for non-responders 
starting at week 8. If the patient failed to respond within 8 weeks 
after dose escalation, they were discontinued from the active 
treatment period. Patients continued to be monitored every 4 
weeks through to the final OLE study evaluation at week 76.
All authors had access to the study data, and reviewed and 
approved the final manuscript.
efficacy assessments
The primary end point for the induction study was CDAI-70 
response rate (proportion of patients achieving a ≥70-point 
reduction in CDAI score) at weeks 8 or 12. Analysis of the effi-
cacy end points was prespecified based on the modified intent-
to-treat (mITT) population, which included all patients who 
were randomised and received at least one treatment. Sample 
size calculation is described in the online supplementary file. 
Enrolment into the 200 mg group was discontinued due to fatal-
ities in patients with SLE who were treated with this dose in 
a separate trial9 (NCT01405196). Power calculations were not 
impacted for comparisons between PF-04236921 10 or 50 mg 
and placebo. However, because the 200 mg arm was stopped 
early, the sample size was less than the planned sample size 
(n=40 instead of 60); hence, the data were not included in the 
primary efficacy analysis.
Secondary end points in the induction study were CDAI-70 and 
CDAI-100 response rates, CDAI remission (CDAI score <150) 
rates and mean changes from baseline in CDAI scores at weeks 2 
through 12. Exploratory end points included comparisons with 
placebo in the changes from baseline in total scores at week 12 of 
the Inflammatory Bowel Disease Questionnaire (IBDQ) and the 
European Quality of Life 5 Dimensions Questionnaire (EQ-5D).
As per protocol, the efficacy, health outcomes and biomarker 
end points were analysed using the mITT population, defined 
as all randomised subjects who received at least one dose of 
PF-04236921. The CDAI response and remission rates at weeks 
2 through 12 were analysed using a longitudinal model, described 
as generalised linear mixed-effects model (statistical methods are 
discussed in the online supplementary file), containing fixed 
factors of treatment group, visit and treatment by visit and a 
random effect for patient and baseline covariates, as per the stan-
dard approach for phase II data analyses.
The primary objective of the OLE study was safety. The 
CDAI instrument that was used to assess efficacy in the induc-
tion trial is complicated and intensive. Since efficacy was an 
exploratory end point in the OLE, the simpler Harvey-Brad-
shaw Index (HBI; online supplementary table s1) was used to 
evaluate disease activity and was assessed in all patients who 
had received at least one dose of PF-04236921 in the OLE 
(exploratory efficacy end points and analysis are described in the 
online supplementary file).
The percentage of patients requiring dose escalation, including 
visit date, was recorded.
Pharmacokinetic, pharmacodynamics and immunogenicity 
assessments are described in the online supplementary file.
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Figure 1 Patient disposition. AE, adverse event; ITT, intent to treat; OLE, open-label extension.
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safety assessments
Treatment-emergent adverse events (TEAEs) and SAEs, as well as 
the proportions of patients experiencing events, were reported 
throughout the study. Other safety considerations are included 
in the online supplementary file.
results
Patient allocation and demographics
Patients were enrolled from February 2011 to June 2014, 
with the last patient visit in February 2015 (induction study) 
and March 2016 (OLE). Of 633 screened patients, 249 were 
randomised, 247 were included in the safety population and 245 
were included in the mITT population (figure 1). Baseline demo-
graphics and characteristics were generally balanced between 
groups (table 1). Patient screen failures, corticosteroid use 
and endoscopy findings at baseline are described in the online 
supplementary file.
Fifty patients (20.1%) discontinued during the 12-week treat-
ment period, and the rates were not meaningfully different 
across the groups, with the exception of the 200 mg group.
In the OLE, 191 patients were enrolled and treated (figure 1), 
of whom 89 were responders (achieving CDAI-70 at week 12 in 
the induction study) and 99 non-responders at entry (table 2). 
Sixty-nine patients (36.1%) completed 48 weeks’ treatment. 
The responder and non-responder statuses for completers and 
discontinued subjects are also provided in table 2.
efficacy of induction therapy
In the induction study, PF-04236921 50 mg met the primary end 
point: CDAI-70 response rates were significantly greater than 
with placebo at weeks 8 (49.3% vs 30.6%, P<0.05) and 12 
(47.4% vs 28.6%, P<0.05) (figure 2).
Separation from placebo was observed as early as week 4, 
particularly for CDAI-70 response and remission (figure 3A,C), 
as well as mean change in CDAI score at weeks 4, 8, 10 and 12 
(figure 3D). Notably, CDAI remission rates with PF-04236921 
50 mg were significantly greater than with placebo at week 12 
(27.4% vs 10.9%, respectively) with a difference of 16.5% 
(P<0.05). PF-04236921 50 mg provided statistically significant 
improvements over placebo for nearly all time points for CDAI 
remission (figure 3C,D).
Comparison of 50 mg with placebo for CDAI-100 was signifi-
cant at week 6, but not at week 12 (figure 3B).
The 10 mg dose did not meet the primary end point. Numer-
ical improvements were noted in the continuous CDAI score 
for 10 mg compared with placebo but were not significant 
(figure 3D). There were no significant differences observed 
across groups for the number of patients taking oral steroids 
and/or the median dose usage over time.
A separate longitudinal analysis model was used to evaluate 
efficacy outcomes for the PF-04236921 200 mg dose (online 
supplementary figure s1). Estimates for CDAI-70 response rates 
at week 8 were 39.0% with PF-04236921 200 mg and 28.8% 
with placebo; corresponding values at week 12 were 41.7% and 
26.7%, respectively, and were not statistically significant. Results 
of sensitivity analysis of the efficacy end points and post-hoc 
subgroup analyses are described in the online supplementary file.
Statistical analyses showed that differences from placebo in the 
change from baseline in IBDQ total scores ranged from −13.6 to 
−4.7 for PF-04236921 10 mg and from −5.7 to 2.2 for 50 mg, 
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table 1 Patient demographics and disease characteristics at baseline
Placebo (n=69) 10 mg (n=67) 50 mg (n=71) 200 mg (n=40)
Mean age, years (SD) 38.4 (13.6) 38.9 (12.9) 38.9 (13.1) 42.2 (13.2)
Female, n (%) 38 (55.1) 34 (50.7) 44 (62.0) 25 (62.5)
Mean body mass index, kg/m2 (SD) 25.8 (7.4) 24.8 (5.7) 25.0 (6.0) 22.9 (4.6)
Median disease duration, years (range) 10.0 (1.2–36.0) 11.0 (0.7–49.0) 9.8 (0.3–43.0) 11.5 (0.3–39.0)
Mean CDAI score* (SD) 320.7 (64.2) 319.9 (61.9) 296.7 (63.3) 337.4 (73.4)
Median CRP levels, mg/L (range) 20.4 (0.1–114.7) 16.4 (0.1–139.8) 21.1 (1.4–106.3) 32.2 (1.0–88.4)
Prior anti-TNF exposure, n (%)
  Relapsed after at least one anti-TNF 37 (53.6) 33 (49.3) 34 (47.9) 18 (45.0)
  Primary non-responder to at least one anti-TNF 16 (23.2) 15 (22.4) 14 (19.7) 10 (25.0)
  Intolerant to at least one anti-TNF 11 (15.9) 15 (22.4) 18 (25.4) 9 (22.5)
  Discontinued anti-TNF for other reason† 5 (7.2) 4 (6.0) 5 (7.0) 3 (7.5)
Current use of immunosuppressive therapy, n (%)
  Azathioprine 10 (14.5) 10 (14.9) 13 (18.3) 5 (12.5)
  6-Mercaptopurine 2 (2.9) 2 (3.0) 3 (4.2) 1 (2.5)
  Methotrexate 4 (5.8) 8 (11.9) 7 (9.9) 2 (5.0)
  No immunosuppressive therapy 53 (76.8) 47 (70.1) 48 (67.6) 32 (80.0)
Current use of corticosteroids, n (%; median dose) 35 (50.7; 20 mg) 17 (25.4; 15 mg) 29 (40.8; 20 mg) 19 (47.5; 20 mg)
Presence of ulcers, n (%) 69 (100) 66 (98.5) 71 (100) 40 (100)
Sites of involvement
  Ileum 40 (58) 48 (71.6) 33 (46.5) 27 (67.5)
  Right colon 34 (49.3) 25 (37.3) 28 (39.4) 19 (47.5)
  Transverse colon 30 (43.5) 23 (34.3) 34 (47.9) 21 (52.5)
  Left colon 46 (66.7) 32 (47.8) 50 (70.4) 29 (72.5)
  Rectum 38 (55.1) 30 (44.8) 47 (66.2) 23 (57.5)
SES-CD subscores, mean (SD)
  Ileum 3.9 (3.5) (n=67) 4.4 (3.4) (n=66) 3.6 (3.8) (n=68) 4.6 (3.7) (n=40)
  Right colon 3.0 (3.4) (n=66) 2.2 (2.7) (n=66) 2.2 (2.8) (n=67) 2.8 (3.2) (n=39)
  Transverse colon 2.5 (3.1) (n=68) 2.0 (2.9) (n=67) 2.8 (3.3) (n=70) 3.4 (3.4) (n=39)
  Left colon 4.0 (3.4) (n=69) 3.2 (3.6) (n=67) 4.6 (3.3) (n=70) 5.1 (3.8) (n=40)
  Rectum 3.4 (3.4) (n=69) 3.1 (3.5) (n=67) 4.1 (3.4) (n=71) 3.8 (3.7) (n=40)
*The mean baseline CDAI score was different between the 50 mg and placebo groups, and this difference was statistically significant.
†This category captures discontinuations unrelated to efficacy or safety and may include financial/insurance-based issues to continuing the treatment.
CDAI, Crohn’s Disease Activity Index; CRP, C-reactive protein; SES-CD, Simple Endoscopic Score for CD; TNF, tumour necrosis factor.
table 2 Patient disposition in the open-label extension study
PF-04236921
Enrolled and treated* 191
  Responder at entry 89
  Non-responder at entry 99
  Responder status missing at entry 3
End of treatment: completed 69
  Baseline HBI data 65
  Responders 36
  Non-responders 29
End of treatment: discontinued 122
  Baseline HBI data 121
  Responders 51
  Non-responders 70
End of study (includes follow-up period): completed 111
Analysed for safety 191
Analysed for efficacy 189†
*Patients in the prior induction study achieving CDAI-70 (proportion of patients 
who achieved a ≥70-point reduction in Crohn’s Disease Activity Index (CDAI) score) 
response were considered responders at entry and those patients not achieving 
CDAI-70 response were considered non-responders at entry.
†Patients who received at least one dose of PF-04236921 in this study but excludes 
two patients with a quality issue.
HBI, Harvey-Bradshaw Index.
Inflammatory bowel disease
and were not statistically significant (one-sided P values ≥0.05) 
at weeks 4, 8 and 12. At the same time points, differences from 
placebo in the change from baseline in the EQ-5D utility index 
ranged from −0.013 to 0.018 for PF-04236921 10 mg and from 
0.011 to 0.043 for 50 mg, and were not statistically significant 
(one-sided P values ≥0.05).
long-term effects of PF-04236921
For the 191 patients who entered the OLE study, 89 (46%) were 
assessed as CDAI responders at OLE baseline, and 31% were 
CDAI remitters at baseline. As an exploratory endpoint, mainte-
nance of response by PF-04236921 was assessed using HBI. For 
the subset of patients who had been on active therapy and were 
responders at baseline for the OLE (n=65), the response and 
remission rates were 40% (online supplementary figure s3) and 
32%, respectively, by week 48 of the OLE.
For the overall OLE population (n=191), 77.8% of 
patients (SE 0.073) had their dose escalated to 100 mg 
between weeks 8 and 48. Time to dose escalation is shown in 
online supplementary figure s4.
Pharmacokinetic and pharmacodynamic outcomes
Changes in serum concentrations of PF-04236921 and CRP in 
the induction trial (online supplementary figures s5 and s6) and 
changes in serum concentrations of PF-04236921 in the OLE 
group.bmj.com on January 18, 2018 - Published by http://gut.bmj.com/Downloaded from 
5Danese S, et al. Gut 2017;0:1–9. doi:10.1136/gutjnl-2017-314562
Figure 2 Primary end point: CDAI-70 response rates at weeks 8 and 12 (generalised linear mixed model; modified intention-to-treat population). 
*P<0.05 versus placebo. CDAI, Crohn’s Disease Activity Index; CDAI-70, proportion of patients who achieved a ≥70-point reduction in CDAI score.
Inflammatory bowel disease
(online supplementary figure s7) are described in the online 
supplementary file.
Identification of antidrug antibodies (ADAs) was rare across the 
two studies. Of 680 serum samples collected for ADA analysis in 
the induction study, one (0.1%) was confirmed as ADA-positive 
(50 mg, week 4) and also tested positive for neutralising antibodies 
(Nab). These findings did not appear to be associated with any 
TEAEs or pharmacokinetic effects in this patient. In the OLE study, 
among 1159 serum samples, six samples from one patient were 
confirmed ADA positive and 1/6 was confirmed Nab-positive. 
There was no discernible impact of this positive ADA result on the 
patient’s pharmacokinetic profile.
Serum CRP levels were continuously suppressed during the 
treatment period in the OLE study, returning to baseline during 
the follow-up period. At the OLE baseline, the median serum 
concentration of CRP was 4.030 mg/mL (−74.3% change from 
induction study baseline). The median per cent changes from 
induction study baseline in serum concentrations of CRP were 
−93.5% and −89.2%, respectively, at weeks 4 and 48. By the 
end of the study (week 76), the median per cent change from 
induction study baseline was −57.9%.
Results from faecal calprotectin assays were highly variable 
at baseline and over time in all groups. No significant treatment 
effects of PF-04236921 on faecal calprotectin were identified.
safety outcomes
Rates of TEAE and SAEs are described in table 3 and online 
supplementary table s2 for the induction and OLE studies, 
respectively. For both studies, the most frequent TEAEs and 
SAEs with PF-04236921 were CD related (including wors-
ening, exacerbation and flare of CD and abdominal pain) and 
nasopharyngitis.
During the OLE study, there were 890 AEs in 171 patients 
(89.5%) and most AEs were mild or moderate in severity. A total 
of 58 patients (30.4%) experienced SAEs of all causalities in the 
treatment period of the OLE study.
There was one death in the induction study, which occurred 
in the 50 mg group, in a patient in their mid-70s who had a 
54-year history of ileocolonic CD without prior surgery and a 
medical history of chronic obstructive pulmonary disease. The 
patient died of respiratory failure secondary to pneumonia on 
day 96, judged as unrelated to treatment by the investigator. The 
patient had a colectomy on day 80 and experienced a postoper-
ative complication of respiratory failure. The full narrative can 
be found in the online supplementary file. There were no deaths 
in the OLE.
Injection-site TEAEs were infrequent (placebo, n=4; 
PF-04236921 10 mg, n=2; 50 mg, n=7; 200 mg, n=6) in the 
induction study, and there were 42 in the OLE.
In light of the concern for risk of GI perforation and abscess 
with this mechanism of action (and because these events may 
be reported by investigators as infections or GI events), online 
supplementary table s3 lists the events of abscess and perforation 
identified by the Standardised Medical Dictionary for Regula-
tory Activities Queries search. During the induction study, six 
patients experienced seven SAEs of abscess or perforation, all 
in PF-04236921-treated patients. In the OLE study treatment 
period, 10 patients experienced 12 SAEs of abscess and perfora-
tion (50 mg, n=6; 100 mg, n=4).
DIscussIOn
The phase II induction trial supports the efficacy of PF-04236921 
50 mg SC in anti-TNF-experienced patients with moderate-to-se-
vere CD, administered on days 1 and 28, for inducing response 
and remission over 12 weeks. The 50 mg dose met the primary 
end point, significantly improving CDAI-70 response rates versus 
placebo at weeks 8 and 12. At the time the study was designed, 
the use of the CDAI instrument for the primary end point was 
standard. Using the more rigorous CDAI end point(s), CDAI 
remission for the 50 mg dose was significant when compared 
with placebo at weeks 8 and 12, but the CDAI-100 did not 
reach significance at these time points. While randomisation 
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Figure 3 CDAI outcomes from week 2 to week 12 by treatment group: (A) CDAI-70 response rate; (B) CDAI-100 response rate; (C) CDAI remission 
rate; and (D) mean changes in CDAI score from baseline (generalised linear mixed model; modified intention-to-treat population). *P<0.05 versus 
placebo. CDAI, Crohn’s Disease Activity Index; CDAI-70/100, proportion of patients who achieved a 70/100-point reduction in CDAI score.
Inflammatory bowel disease
was generally balanced across the arms, there was a numerically 
lower baseline CDAI score in the 50 mg group that may have 
contributed to the lower CDAI-100 response rates in that group 
(eg, subjects who entered the study with scores between 220 
and 250 would be unable to numerically achieve a 100-point 
decrease). The changes in continuous CDAI score are supportive 
of the rapid onset of action with separation from placebo as 
early as week 4 and maintained through week 12. Newer end 
points for CD that include measures of mucosal healing cannot 
be discerned from this study as endoscopy was not performed in 
a systematic manner.
The primary analysis method for this trial was a longitudinal 
method that incorporated all data, even from those patients who 
discontinued prior to week 12. The non-responder imputation 
(NRI) analysis is cross-sectional (using responder data only from 
week 12) that is more commonly used in phase III confirmatory 
studies, where the sample size is substantially larger. In addition, 
the NRI imputes any missing data as non-responder, which is 
the most conservative form of imputation. The longitudinal 
mixed-effect model repeat measurement method is considered 
to be more powerful than the NRI method for this explor-
atory phase II study. Nonetheless, as a post-hoc analysis, the 
data were reanalysed using the NRI approach. The difference 
between 50 mg and placebo at week 12 for CDAI-70 was 8% 
(95% CI −6% to 21%) and for CDAI remission was 14% (95% 
CI 0.03 to 0.24) (online supplementary table s4).
In this CD study, the early termination of the 200 mg dose 
group resulted in a much smaller sample size. Given this limitation, 
there did not appear to be additional benefit for the 200 mg dose 
to balance the higher rates of SAEs and discontinuations due to 
TEAEs.
For patients who entered the OLE trial as responders and who 
had been on active drug in the induction period (n=65), the HBI 
response and remission rates were 40% and 32% at week 48. By 
inspection of PF-04236921 concentrations, the loss of response 
over time in more than half of the patients did not appear to be asso-
ciated with decrease of drug levels and/or with occurrence of ADAs, 
as has been commonly observed for other anticytokine therapies. 
Maintenance for patients induced on anti-IL-6 therapy is impacted 
by attenuation of unknown cause and will require development of 
new optimisation of treatment strategies that could include high(er) 
dose and/or longer duration of induction or alternate drug combi-
nations in order to avoid immunological breakthroughs.
Occurrence of GI perforation has been reported in patients 
with rheumatoid arthritis treated with a humanised monoclonal 
antibody against the IL-6 receptor, tocilizumab.10 11 Most cases 
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table 3 Treatment-emergent adverse events during the 12-week induction trial
Placebo (n=69) 10 mg (n=67) 50 mg (n=71) 200 mg (n=40)
Any adverse events, n (%) 63 (91.3) 60 (89.6) 58 (81.7) 33 (82.5)
Severe adverse events, n (%) 5 (7.2) 12 (17.9) 12 (16.9) 5 (12.5)
Serious adverse events, n (%) 9 (13.0) 7 (10.4) 9 (12.7) 11 (27.5)
  GI disorders* 5 (7.2) 3 (4.5) 7 (9.9) 8 (20.0)
  Serious infections and infestations 
   Sepsis 1 (1.4) – – –
   Anal abscess – 1 (1.5) 2 (2.8) –
   Groin abscess – – – 1 (2.5) 
   Intestinal abscess – 1 (1.5) – – 
   Pneumonia – – – 1 (2.5) 
  Deaths 0 (0.0) 0 (0.0) 1 (1.4) 0 (0.0)
Discontinuations due to adverse events, n (%) 7 (10.1) 6 (9.0) 6 (8.5) 8 (20.0)
Temporary discontinuation due to adverse events, n (%) 0 (0.0) 0 (0.0) 1 (1.4) 0 (0.0)
Common adverse events (≥5% in any treatment group), n (%)
  Crohn’s disease† 8 (11.6) 3 (4.5) 10 (14.1) 8 (20.0)
  Abdominal pain 8 (11.6) 6 (9.0) 8 (11.3) 6 (15.0)
  Headache 6 (8.7) 5 (7.5) 8 (11.3) 2 (5.0)
  Nasopharyngitis 3 (4.3) 10 (14.9) 7 (9.9) 3 (7.5)
  Nausea 1 (1.4) 7 (10.4) 7 (9.9) 1 (2.5)
  Rash 1 (1.4) 2 (3.0) 7 (9.9) 1 (2.5)
  Arthralgia 8 (11.6) 5 (7.5) 5 (7.0) 0 (0.0)
  Erythema 0 (0.0) 1 (1.5) 4 (5.6) 1 (2.5)
  Fatigue 0 (0.0) 2 (3.0) 4 (5.6) 0 (0.0)
  Proctalgia 0 (0.0) 2 (3.0) 4 (5.6) 0 (0.0)
  Pyrexia 8 (11.6) 5 (7.5) 4 (5.6) 1 (2.5)
  Upper respiratory tract infection 2 (2.9) 0 (0.0) 4 (5.6) 0 (0.0)
  Back pain 4 (5.8) 4 (6.0) 3 (4.2) 1 (2.5)
  Peripheral oedema 2 (2.9) 2 (3.0) 3 (4.2) 2 (5.0)
  Urinary tract infection 3 (4.3) 2 (3.0) 3 (4.2) 5 (12.5)
  Vomiting 2 (2.9) 3 (4.5) 3 (4.2) 2 (5.0)
  Gastroenteritis 1 (1.4) 0 (0.0) 1 (1.4) 2 (5.0)
  Constipation 2 (2.9) 2 (3.0) 0 (0.0) 2 (5.0)
  Upper abdominal pain 0 (0.0) 1 (1.5) 0 (0.0) 3 (7.5)
*GI disorders include Crohn’s disease, abdominal pain, anal fistula, intestinal perforation, intestinal stenosis, colitis, hematochezia and acute pancreatitis.
†Includes worsening, exacerbation and flare of Crohn’s disease.
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occurred in patients with diverticulitis and those receiving 
non-steroidal anti-inflammatory drugs and/or long-term corti-
costeroids.11 Given this observation, as well as the association 
between CD and GI perforation, fistula formation and abscess,12 
GI perforation was a potential safety concern for PF-04236921 
in CD. To reduce the risk, patients with a history of diverticu-
litis and patients with active fistulae or abscess were excluded. 
Patients were allowed to enrol in this study if computed tomog-
raphy-MRI was performed within 6 months of screening to 
exclude active fistula or abscess. We acknowledge that imaging 
conducted during the screening period may have been more 
appropriate to exclude patients with abscess or fistula particu-
larly because many of the participants in this trial had exten-
sive disease history (median disease duration approximately 
10 years). There were cases of GI perforation and GI abscesses 
observed in both the induction and OLE studies. In the induction 
period, there did not appear to be an increase in frequency of 
these events with dose, although all six patients with events were 
in the PF-04236921-treated groups in the induction period. The 
interpretation of dose dependency in the OLE is complicated 
by: the lack of a placebo control; subjects having entered the 
study from different dose levels (including placebo); and the 
fact that a one-time dose escalation was allowed in the OLE. 
The DMC reviewed all cases and did not recommend changes in 
treatment. Most cases of GI perforation or abscess were identi-
fied in regions of previous disease involvement and/or surgery, 
making it difficult to discriminate the impact of disease progres-
sion versus study drug. Nonetheless, because the events occurred 
only in the PF-04236921 groups (compared with placebo), this 
represents a signal that requires careful attention in future clin-
ical trials.
Although anti-TNF therapy represents a significant land-
mark in the treatment of CD, many patients experience 
primary non-response or relapse.5 The present study suggests 
that targeting IL-6 may provide a further therapeutic option 
for this population in whom CDAI response and remission 
rates for a second biologic are modest, as shown in trials with 
vedolizumab (44% and 39%, respectively, in a population of 
50% anti-TNF-experienced patients),13 ustekinumab (59% and 
53%, respectively, in a broad population; and 41% remission 
in the anti-TNF-experienced subgroup)14 and adalimumab (43% 
[CDAI-70] and 36%, respectively, in a broad population)1 at the 
approximate 1-year end point (values are not placebo adjusted 
to allow comparison with results in this study). The outcomes 
with PF-04236921 are particularly encouraging in the context 
of a very difficult-to-treat population: in addition to inadequate 
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response to one or more prior anti-TNF therapies, patients had 
a median disease duration of approximately 10 years and many 
had undergone previous resection. Patients with high baseline 
CRP levels (≥5.0 mg/L) were enrolled (elevated CRP transcrip-
tionally controlled by IL-6) because this population may be 
expected to be more susceptible to anti-IL-6 therapy.6 8
In the induction study, the reduction in serum CRP 
(a pharmacodynamic marker of IL-6 suppression) appeared to 
increase monotonically as dose increased, reaching 95% reduc-
tion from baseline for the 200 mg dose group at week 12. The 
50 mg dose was associated with a median reduction of 86.3% 
from baseline and was the most effective dose in the induction 
study based on CDAI. From the available data, it is not clear that 
the additional pharmacological suppression provided by 200 mg 
leads to greater benefit compared with 50 mg. No significant 
changes were observed in the faecal calprotectin marker for any 
of the dose groups.
The 50 mg dose group met the primary end point for CDAI-70 
response rate in this study and demonstrated statistical signif-
icance for the secondary end point of CDAI remission rate. 
The overall benefit/risk profile for PF-04236921 appears to be 
acceptable for the continued development of this treatment in 
this refractory CD population. However, the signals of GI perfo-
ration and abscess do require careful consideration and charac-
terisation during future clinical development.
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